IL184532A0 - Novel adenosine a3 receptor modulators - Google Patents

Novel adenosine a3 receptor modulators

Info

Publication number
IL184532A0
IL184532A0 IL184532A IL18453207A IL184532A0 IL 184532 A0 IL184532 A0 IL 184532A0 IL 184532 A IL184532 A IL 184532A IL 18453207 A IL18453207 A IL 18453207A IL 184532 A0 IL184532 A0 IL 184532A0
Authority
IL
Israel
Prior art keywords
receptor modulators
novel adenosine
adenosine
novel
modulators
Prior art date
Application number
IL184532A
Other languages
English (en)
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of IL184532A0 publication Critical patent/IL184532A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL184532A 2005-02-02 2007-07-10 Novel adenosine a3 receptor modulators IL184532A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64972605P 2005-02-02 2005-02-02
US11/344,295 US7435740B2 (en) 2005-02-02 2006-01-31 Adenosine A3 receptor modulators
PCT/US2006/003477 WO2006083916A2 (en) 2005-02-02 2006-02-01 Novel adenosine a3 receptor modulators

Publications (1)

Publication Number Publication Date
IL184532A0 true IL184532A0 (en) 2007-10-31

Family

ID=36777854

Family Applications (1)

Application Number Title Priority Date Filing Date
IL184532A IL184532A0 (en) 2005-02-02 2007-07-10 Novel adenosine a3 receptor modulators

Country Status (11)

Country Link
US (1) US7435740B2 (enExample)
EP (1) EP1845993A4 (enExample)
JP (1) JP2008538099A (enExample)
KR (1) KR20070100331A (enExample)
AU (1) AU2006210817B2 (enExample)
BR (1) BRPI0606750A2 (enExample)
CA (1) CA2596612A1 (enExample)
IL (1) IL184532A0 (enExample)
MX (1) MX2007008501A (enExample)
NZ (1) NZ556649A (enExample)
WO (1) WO2006083916A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
US8765775B2 (en) 2008-01-24 2014-07-01 Universitaet Zuerich Anti-angiogenic compounds
US20110190324A1 (en) * 2008-07-16 2011-08-04 Edward Leung Methods of treating atherosclerosis
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses

Also Published As

Publication number Publication date
JP2008538099A (ja) 2008-10-09
BRPI0606750A2 (pt) 2009-07-14
AU2006210817A2 (en) 2006-08-10
US7435740B2 (en) 2008-10-14
CA2596612A1 (en) 2006-08-10
AU2006210817B2 (en) 2010-12-23
EP1845993A2 (en) 2007-10-24
KR20070100331A (ko) 2007-10-10
EP1845993A4 (en) 2009-03-11
WO2006083916A2 (en) 2006-08-10
WO2006083916A3 (en) 2007-12-21
US20060178385A1 (en) 2006-08-10
MX2007008501A (es) 2007-09-14
NZ556649A (en) 2010-03-26
AU2006210817A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
GB0400440D0 (en) Receptor modulators
SI1928845T1 (sl) Aminodiazepini kot modulatorji Tollu podobnega receptorja
ZA200805242B (en) GABAB receptor modulators
EP2179061A4 (en) GREAT LIKE RECEPTOR MODULATORS
IL225446A0 (en) Benzozepines are converted at position 8 as toll-like receptor modulators
IL184657A0 (en) Adam-9 modulators
GB0509275D0 (en) Synthetic receptor
ZA200805160B (en) Imidazoles as GABAB receptor modulators
IL189846A0 (en) Theramutein modulators
GB0610583D0 (en) Anchorages
GB0509276D0 (en) Synthetic receptor
ZA200800690B (en) Non-steroidal progesterone receptor modulators
EP1845993A4 (en) NOVEL ADENOSINE AS A3 RECEPTOR MODULATOR
ZA200806237B (en) Cannibinoid receptor modulators
EP1945213A4 (en) MODULATORS OF THE R3-PIPERIDINE-4-YL-INDOLE ORL-1 RECEPTOR
GB0414798D0 (en) Receptor
GB0516946D0 (en) Receptor
GB0413872D0 (en) Receptor
GB0522484D0 (en) Receptor
GB0510253D0 (en) Receptor
GB0522077D0 (en) Receptor
GB0522394D0 (en) Receptor
IL178010A0 (en) Progesterone receptor modulators
GB0413096D0 (en) Receptor
GB0427025D0 (en) Receptor